Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Regentis Biomaterials Ltd. Ordinary Shares (NY:RGNT)

1.525 +0.015 (+0.99%)
Delayed Quote Updated: 10:15 AM EDT, Oct 15, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Regentis Biomaterials Ltd. Ordinary Shares

< Previous 1 2 Next >
InvestorNewsBreaks – Regentis Biomaterials Ltd. (NYSE American: RGNT) Reports Strong Surgeon Interest in GelrinC at International Cartilage Summit
Via Investor Brand Network
MissionIRNewsBreaks – Regentis Biomaterials Ltd. (NYSE American: RGNT) to Present at 2026 ThinkEquity Conference on Oct. 15
Via Investor Brand Network
News headline image
Regentis Biomaterials Reports Strong Surgeon Interest in GelrinC(R) at 8th ICRS Summit in Portugal
Engagement with leading orthopedic surgeons and cartilage repair specialists highlights growing awareness of GelrinC's off-the-shelf regenerative technology GelrinC is CE Mark approved in Europe, where... 
From Regentis Biomaterials Ltd
Via ACCESS Newswire
Regenerative Hydrogel Is Redefining Cartilage Repair as Regentis Advances GelrinC
Via Investor Brand Network
News headline image
Regentis Biomaterials to Present at the 2026 ThinkEquity Conference on October 15 in New York City
From Regentis Biomaterials Ltd
Via ACCESS Newswire
BioMedNewsBreaks — Regentis Biomaterials Ltd. (NYSE American: RGNT) Seeks to Redefine Knee Cartilage Repair with Resorbable Hydrogel Technology
Via Investor Brand Network
Regentis Biomaterials Is Addressing the ‘Short-Term Relief, Long-Term Failure’ Problem in Knee Cartilage Repair
Via Investor Brand Network
Regentis Biomaterials and the Shift from Symptom Management to Structural Repair in Knee Cartilage Care
Via Investor Brand Network
BioMedNewsBreaks — Regentis Biomaterials Ltd. (NYSE American: RGNT) CEO Discusses GelrinC(R), U.S. Pivotal Study and European Commercialization on BioMedWire Podcast
Via Investor Brand Network
MissionIRNewsBreaks – Regentis Biomaterials Ltd. (NYSE American: RGNT) Moves GelrinC Into Pivotal Stage of Development
Via Investor Brand Network
BioMedNewsBreaks — Regentis Biomaterials Ltd. (NYSE American: RGNT) Reports First Half 2026 Results, Advances GelrinC(R) Pivotal Trial
Via Investor Brand Network
Regentis Biomaterials Ltd. (NYSE American: RGNT) Advances GelrinC as a Potential New Approach to Knee Cartilage Repair
Via Investor Brand Network
News headline image
Regentis Biomaterials Reports First Half 2026 Financial Results and Provides Corporate Update
Advances GelrinC ® U.S. pivotal trial with 43 patients treated; Completion of enrollment expected by approximately year end 2026 Expands European commercialization readiness, including surgeon training... 
From Regentis Biomaterials Ltd
Via ACCESS Newswire
NetworkNewsBreaks – Regentis Biomaterials Ltd.’s (NYSE American: RGNT) GelrinC Advances Toward New Era of Regenerative Orthopedic Care
Via Investor Brand Network
MissionIRNewsBreaks – Regentis Biomaterials Ltd. (NYSE American: RGNT) Expands GelrinC Clinical and Commercial Pathways
Via Investor Brand Network
BioMedNewsBreaks — Regentis Biomaterials Ltd. (NYSE American: RGNT) Marks Key IP Milestone for GelrinC Manufacturing
Via Investor Brand Network
Topics Intellectual Property
InvestorNewsBreaks – Regentis Biomaterials Ltd. (NYSE American: RGNT) Builds Commercial Case for GelrinC in Multi-Billion Knee Cartilage Repair Market
Via Investor Brand Network
Regentis Biomaterials Ltd. (NYSE American: RGNT) Moves GelrinC Along Parallel US Clinical and European Commercial Tracks
Via Investor Brand Network
Regentis Biomaterials Ltd. (NYSE American: RGNT) Builds a Manufacturing and Intellectual Property Powerhouse for the Global Cartilage Repair Market
Via Investor Brand Network
Topics Intellectual Property
NetworkNewsBreaks – Regentis Biomaterials Ltd. (NYSE American: RGNT) Moves GelrinC Closer to Regulatory and Commercial Milestones
Via Investor Brand Network
Surgeon, Payer, Patient Win: The Economic and Workflow Advantages Positioning GelrinC as a New Standard of Care for Knee Cartilage Repair
Via Investor Brand Network
BioMedNewsBreaks — Regentis Biomaterials Ltd. (NYSE American: RGNT) Advances Regenerative Solution for Major Unmet Need in Cartilage Repair
Via Investor Brand Network
InvestorNewsBreaks – Regentis Biomaterials Ltd. (NYSE American: RGNT) Targets $3 Billion Cartilage Repair Market with Cell-Free Gelrin C
Via Investor Brand Network
Regentis Biomaterials Ltd. (NYSE American: RGNT) Builds Commercial and Regulatory Momentum as GelrinC Advances Toward Key Clinical and Regulatory Milestones
Via Investor Brand Network
Regentis Biomaterials Ltd. (NYSE American: RGNT) Positioned to Benefit as Regenerative Medicine Reshapes the Growing $3 Billion Cartilage Repair Market
Via Investor Brand Network
BioMedNewsBreaks — Regentis Biomaterials Ltd. (NYSE American: RGNT) Receives Japan Patent Allowance for GelrinC Manufacturing Technology
Via Investor Brand Network
Topics Intellectual Property
News headline image
Regentis Receives Japanese Patent allowance, Strengthening its Global GelrinC Intellectual Property Portfolio with New Proprietary Manufacturing Technology
From Regentis Biomaterials Ltd
Via ACCESS Newswire
BioMedNewsBreaks — Regentis Biomaterials Ltd. (NYSE American: RGNT) Receives European Approval for Next-Generation GelrinC Manufacturing Process
Via Investor Brand Network
News headline image
Regentis Receives European Regulatory Approval for New GelrinC Manufacturing Process, Increasing Production Yield by 400% Ahead of European Commercial Launch
From Regentis Biomaterials Ltd
Via ACCESS Newswire
The $15 Billion Knee OA Spending Gap: Why Gelrin C Is the Smartest Investment in Cartilage Economics
Via Investor Brand Network
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.